Opinion of the Transparency Council – Treatment of Gaucher disease type I and type III (ICD-10 E 75.2)

At its meeting on 14 April 2025, the Transparency Council adopted opinion No. 61/2025 on amendments to the B.23 drug program “Treatment of Gaucher disease type I and type III (ICD-10 E 75.2)”